Skip to main navigation
Skip to search
Skip to main content
MD Anderson Cancer Center Home
Help & FAQ
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Search by expertise, name or affiliation
Bruton Tyrosine Kinase Inhibitors: Present and Future
Jan A. Burger
Leukemia
Research output
:
Contribution to journal
›
Review article
›
peer-review
128
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Bruton Tyrosine Kinase Inhibitors: Present and Future'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
100%
Bruton Tyrosine Kinase Inhibitor
100%
Adverse Effect
66%
B Cell
66%
Mantle Cell Lymphoma
66%
Bruton Tyrosine Kinase
66%
Ibrutinib
66%
Combination Therapy
33%
Leukemia Cell
33%
Drug Resistance
33%
Lymph Duct
33%
Chronic Graft Versus Host Disease
33%
Waldenström's Macroglobulinemia
33%
Protein Tyrosine Kinase
33%
B Lymphocyte
33%
Cell Surface Receptor
33%
MALT Lymphoma
33%
Drive
33%
Signal Transduction
33%
Lymphocytic Lymphoma
33%
Lymphocyte Antigen Receptor
33%
Antigen Receptor Signaling
33%
Cell Antigen
33%
Treatment Duration
33%
Keyphrases
Bruton Tyrosine Kinase Inhibitor
100%
BTK Inhibitor
100%
Chronic Lymphocytic Leukemia Cells
75%
Adverse Effects
50%
Mantle Cell Lymphoma
50%
B Cell Receptor
50%
Bruton's Tyrosine Kinase
50%
Ibrutinib
50%
Receptor Tyrosine Kinase
25%
Chemotherapy
25%
Combination Therapy
25%
Signal Transduction
25%
Drug Resistance
25%
B Lymphocytes
25%
Graft-versus-host Disease (GvHD)
25%
First-in-class
25%
Cell Surface Receptor
25%
Waldenström Macroglobulinemia
25%
Small Lymphocytic Lymphoma
25%
Malignant B Cells
25%
Antigen Receptor Signaling
25%
Marginal Zone Lymphoma
25%
Lymphoid Organs
25%
Current Clinical Practice
25%
Long-term Administration
25%